Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZN-e4 in Advanced EGFR-mutated NSCLC
NCT03446417Phase 1Completed
- Sponsor
- Zeno Pharmaceuticals, Inc.
- Start
- Apr 2018
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of ZN-e4 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Zeno Pharmaceuticals, Inc. Primary endpoint: Observed dose limiting toxicities at 21 days. Started Apr 2018; status: completed.
02
Drugs
ZN-e4
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03446417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03446417.